Meeting
2015 Gastrointestinal Cancers Symposium
Impact of FOLFOXIRI regimen on early “Conversion” and long-term outcome in patients with initially unresectable colorectal liver metastases.
Authors
Mitsuo Shimada
Department of Surgery, University of Tokushima, Tokushima, Japan
Mitsuo Shimada , Yuji Morine , Satoru Imura , Tetsuya Ikemoto , Yusuke Arakawa , Shuichi Iwahashi , Yu Saito , Shinichiro Yamada , Jun Higashijima , Chie Takasu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 416)
DOI
10.1200/jco.2015.33.3_suppl.416
Abstract #
416
Poster Bd #
D35
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma
Poster
2016 ASCO Annual Meeting
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.
First Author: Chiara Cremolini
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.
First Author: Kodai Takemori
Poster
2020 ASCO Virtual Scientific Program
Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).
First Author: Gunnar Folprecht